• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MUC1 的抑制促进了胰腺和乳腺癌小鼠模型中髓源性抑制细胞的扩增和抑制功能。

Repression of MUC1 Promotes Expansion and Suppressive Function of Myeloid-Derived Suppressor Cells in Pancreatic and Breast Cancer Murine Models.

机构信息

Department of Bioinformatics, Yale University, New Haven, CT 06520, USA.

Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.

出版信息

Int J Mol Sci. 2021 May 25;22(11):5587. doi: 10.3390/ijms22115587.

DOI:10.3390/ijms22115587
PMID:34070449
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8197523/
Abstract

Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that are responsible for immunosuppression in tumor microenvironment. Here we report the impact of mucin 1 (MUC1), a transmembrane glycoprotein, on proliferation and functional activity of MDSCs. To determine the role of MUC1 in MDSC phenotype, we analyzed MDSCs derived from wild type (WT) and MUC1-knockout (MUC1KO) mice bearing syngeneic pancreatic (KCKO) or breast (C57MG) tumors. We observed enhanced tumor growth of pancreatic and breast tumors in the MUC1KO mice compared to the WT mice. Enhanced tumor growth in the MUC1KO mice was associated with increased numbers of suppressive MDSCs and T regulatory (Tregs) cells in the tumor microenvironment. Compared to the WT host, MUC1KO host showed higher levels of iNOS, ARG1, and TGF-β, thus promoting proliferation of MDSCs with an immature and immune suppressive phenotype. When co-cultured with effector T cells, MDSCs from MUC1KO mice led to higher repression of IL-2 and IFN-γ production by T cells as compared to MDSCs from WT mice. Lastly, MDSCs from MUC1KO mice showed higher levels of c-Myc and activated pSTAT3 as compared to MDSCs from WT mice, suggesting increased survival, proliferation, and prevention of maturation of MDSCs in the MUC1KO host. We report diminished T cell function in the KO versus WT mice. In summary, the data suggest that MUC1 may regulate signaling pathways that are critical to maintain the immunosuppressive properties of MDSCs.

摘要

髓源性抑制细胞(MDSCs)是未成熟的髓系细胞,负责肿瘤微环境中的免疫抑制。在这里,我们报告了跨膜糖蛋白 MUC1 对 MDSC 增殖和功能活性的影响。为了确定 MUC1 在 MDSC 表型中的作用,我们分析了来自野生型(WT)和 MUC1 敲除(MUC1KO)小鼠的 MDSC,这些小鼠携带同基因胰腺(KCKO)或乳腺(C57MG)肿瘤。我们观察到与 WT 小鼠相比,MUC1KO 小鼠的胰腺和乳腺肿瘤生长增强。MUC1KO 小鼠中肿瘤生长增强与肿瘤微环境中抑制性 MDSC 和调节性 T 细胞(Tregs)数量增加有关。与 WT 宿主相比,MUC1KO 宿主显示出更高水平的 iNOS、ARG1 和 TGF-β,从而促进具有不成熟和免疫抑制表型的 MDSC 增殖。当与效应 T 细胞共培养时,与 WT 小鼠的 MDSC 相比,MUC1KO 小鼠的 MDSC 导致 T 细胞产生的 IL-2 和 IFN-γ 的抑制更高。最后,与 WT 小鼠的 MDSC 相比,MUC1KO 小鼠的 MDSC 显示出更高水平的 c-Myc 和激活的 pSTAT3,表明在 MUC1KO 宿主中 MDSC 的存活、增殖和成熟预防增加。我们报告了 KO 小鼠与 WT 小鼠相比,T 细胞功能下降。总之,数据表明 MUC1 可能调节维持 MDSC 免疫抑制特性的关键信号通路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8a6/8197523/761547ad0756/ijms-22-05587-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8a6/8197523/8f71e7bd4b99/ijms-22-05587-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8a6/8197523/948a7d62d294/ijms-22-05587-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8a6/8197523/0571f4e6cb89/ijms-22-05587-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8a6/8197523/6759db2e8bfb/ijms-22-05587-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8a6/8197523/27d7923c366e/ijms-22-05587-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8a6/8197523/761547ad0756/ijms-22-05587-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8a6/8197523/8f71e7bd4b99/ijms-22-05587-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8a6/8197523/948a7d62d294/ijms-22-05587-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8a6/8197523/0571f4e6cb89/ijms-22-05587-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8a6/8197523/6759db2e8bfb/ijms-22-05587-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8a6/8197523/27d7923c366e/ijms-22-05587-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8a6/8197523/761547ad0756/ijms-22-05587-g006.jpg

相似文献

1
Repression of MUC1 Promotes Expansion and Suppressive Function of Myeloid-Derived Suppressor Cells in Pancreatic and Breast Cancer Murine Models.MUC1 的抑制促进了胰腺和乳腺癌小鼠模型中髓源性抑制细胞的扩增和抑制功能。
Int J Mol Sci. 2021 May 25;22(11):5587. doi: 10.3390/ijms22115587.
2
MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia.MUC1介导急性髓系白血病患者髓源性抑制细胞的诱导。
Blood. 2017 Mar 30;129(13):1791-1801. doi: 10.1182/blood-2016-07-730614. Epub 2017 Jan 26.
3
Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5.髓源性抑制细胞通过 IL-7 和 STAT5 抑制肺癌中的 B 细胞反应。
J Immunol. 2018 Jul 1;201(1):278-295. doi: 10.4049/jimmunol.1701069. Epub 2018 May 11.
4
STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients.沉默 STAT3 和激活 TLR7/8 通路重极化并抑制乳腺癌患者来源的髓系抑制细胞。
Front Immunol. 2021 Feb 19;11:613215. doi: 10.3389/fimmu.2020.613215. eCollection 2020.
5
Pancreatic Cancer Cells Isolated from Muc1-Null Tumors Favor the Generation of a Mature Less Suppressive MDSC Population.从 Muc1 缺失肿瘤中分离的胰腺癌细胞有利于生成成熟度较低、抑制作用较弱的 MDSC 群体。
Front Immunol. 2014 Feb 24;5:67. doi: 10.3389/fimmu.2014.00067. eCollection 2014.
6
Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.在 IL-2/αCD40 治疗期间,肿瘤微环境中的调节性 T 细胞和髓源性抑制细胞经历 Fas 依赖性细胞死亡。
J Immunol. 2014 Jun 15;192(12):5821-9. doi: 10.4049/jimmunol.1400404. Epub 2014 May 7.
7
A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model.在小鼠模型中,乳腺癌细胞与髓源性抑制细胞之间的相互激活环通过IL-6转信号促进自发转移。
Breast Cancer Res. 2013;15(5):R79. doi: 10.1186/bcr3473.
8
RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.RPN13/ADRM1抑制剂可逆转髓源性抑制细胞介导的免疫抑制作用。
Oncotarget. 2016 Oct 18;7(42):68489-68502. doi: 10.18632/oncotarget.12095.
9
Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.单核细胞来源的髓样抑制细胞通过 STAT3 对胰腺导管腺癌患者的免疫抑制作用。
J Immunother Cancer. 2019 Sep 18;7(1):255. doi: 10.1186/s40425-019-0734-6.
10
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.通过 TRAIL 受体 2 选择性靶向髓系来源的抑制细胞,以增强 CAR T 细胞疗法治疗乳腺癌的疗效。
J Immunother Cancer. 2021 Nov;9(11). doi: 10.1136/jitc-2021-003237.

引用本文的文献

1
Blood-Based Biomarkers as Predictive and Prognostic Factors in Immunotherapy-Treated Patients with Solid Tumors-Currents and Perspectives.血液生物标志物作为实体瘤免疫治疗患者的预测和预后因素——现状与展望
Cancers (Basel). 2025 Jun 16;17(12):2001. doi: 10.3390/cancers17122001.
2
FANCD2 as a ferroptosis-related target for recurrent implantation failure by integrated bioinformatics and Mendelian randomization analysis.FANCD2 作为复发性着床失败的铁死亡相关靶点:基于整合生物信息学和孟德尔随机化分析。
J Cell Mol Med. 2024 Oct;28(19):e70119. doi: 10.1111/jcmm.70119.
3
MUC1 and MUC16: critical for immune modulation in cancer therapeutics.

本文引用的文献

1
Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics.利用单细胞转录组学定义乳腺癌中髓系来源抑制细胞的出现。
Sci Immunol. 2020 Feb 21;5(44). doi: 10.1126/sciimmunol.aay6017.
2
Microbe-MUC1 Crosstalk in Cancer-Associated Infections.微生物-MUC1 串扰在癌症相关感染中的作用。
Trends Mol Med. 2020 Mar;26(3):324-336. doi: 10.1016/j.molmed.2019.10.003. Epub 2019 Nov 18.
3
Myeloid-Derived Suppressor Cells and Pancreatic Cancer: Implications in Novel Therapeutic Approaches.髓源性抑制细胞与胰腺癌:对新型治疗方法的启示
黏蛋白 1 和黏蛋白 16:癌症治疗中免疫调节的关键。
Front Immunol. 2024 Feb 1;15:1356913. doi: 10.3389/fimmu.2024.1356913. eCollection 2024.
4
Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers.MUC1 和 STAT3 之间的分子串扰影响 Napabucasin 在上皮性癌症中的抗增殖作用。
Sci Rep. 2024 Feb 7;14(1):3178. doi: 10.1038/s41598-024-53549-4.
5
Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment.基于水凝胶的胰腺癌治疗方法
Pharmaceutics. 2023 Oct 4;15(10):2421. doi: 10.3390/pharmaceutics15102421.
6
Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of Pancreatic Cancer Cells Through Inhibition of MUC1 Expression.维生素 D/VDR 信号的激活通过抑制 MUC1 表达逆转胰腺癌细胞对吉西他滨的耐药性。
Dig Dis Sci. 2023 Jul;68(7):3043-3058. doi: 10.1007/s10620-023-07931-3. Epub 2023 Apr 18.
7
MUC1 promotes lung metastases of liver cancer by impairing anti-tumor immunity.MUC1通过损害抗肿瘤免疫促进肝癌的肺转移。
Discov Oncol. 2023 Feb 4;14(1):18. doi: 10.1007/s12672-023-00627-0.
8
Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma.非典型黏蛋白表达预示可切除胰腺导管腺癌患者总体生存更差。
J Immunol Res. 2022 Jul 21;2022:7353572. doi: 10.1155/2022/7353572. eCollection 2022.
9
A prognosis marker MUC1 correlates with metabolism and drug resistance in bladder cancer: a bioinformatics research.MUC1 预后标志物与膀胱癌代谢和耐药性相关:一项生物信息学研究。
BMC Urol. 2022 Jul 25;22(1):114. doi: 10.1186/s12894-022-01067-8.
10
Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma.MUC1过表达在胰腺导管腺癌中诱导非经典TGF-β信号传导。
Front Cell Dev Biol. 2022 Feb 14;10:821875. doi: 10.3389/fcell.2022.821875. eCollection 2022.
Cancers (Basel). 2019 Oct 24;11(11):1627. doi: 10.3390/cancers11111627.
4
Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma.克服免疫抵抗增强新型抗 tMUC1-CAR T 细胞治疗对胰腺导管腺癌的疗效。
Cells. 2019 Sep 11;8(9):1070. doi: 10.3390/cells8091070.
5
Early detection of pancreatic cancer in mouse models using a novel antibody, TAB004.利用新型抗体 TAB004 早期检测小鼠模型中的胰腺癌。
PLoS One. 2018 Feb 20;13(2):e0193260. doi: 10.1371/journal.pone.0193260. eCollection 2018.
6
Myeloid-derived suppressor cells: Important contributors to tumor progression and metastasis.髓源性抑制细胞:肿瘤进展和转移的重要贡献者。
J Cell Physiol. 2018 Apr;233(4):3024-3036. doi: 10.1002/jcp.26075. Epub 2017 Aug 3.
7
MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia.MUC1介导急性髓系白血病患者髓源性抑制细胞的诱导。
Blood. 2017 Mar 30;129(13):1791-1801. doi: 10.1182/blood-2016-07-730614. Epub 2017 Jan 26.
8
Myeloid-Derived Suppressor Cells.髓系来源的抑制细胞
Cancer Immunol Res. 2017 Jan;5(1):3-8. doi: 10.1158/2326-6066.CIR-16-0297.
9
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression.髓源性抑制细胞(MDSC)在癌症进展中的作用
Vaccines (Basel). 2016 Nov 3;4(4):36. doi: 10.3390/vaccines4040036.
10
Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy.髓系来源的抑制细胞:作为入侵者和靶点及其在癌症治疗中的临床意义
Cancer Immunol Immunother. 2016 Jul;65(7):857-67. doi: 10.1007/s00262-016-1849-y. Epub 2016 May 25.